1037211-09-8

Basic information

• Product Name: N-benzyloxycarbonyl-N'-(4-[dimethylazaniumylidene]-1,4-dihydropyridin-1-ylsulfonyl)azanide
• Synonyms: N-benzyloxycarbonyl-N'-(4-[dimethylazaniumylidene]-1,4-dihydropyridin-1-ylsulfonyl)azanide
• CAS NO: 1037211-09-8
• Molecular Weight: 335.384
• Mol File: 1037211-09-8.mol

Chemical Properties

• CAS DataBase Reference: N-benzyloxycarbonyl-N'-(4-[dimethylazaniumylidene]-1,4-dihydropyridin-1-ylsulfonyl)azanide(CAS DataBase Reference)
• NIST Chemistry Reference: N-benzyloxycarbonyl-N'-(4-[dimethylazaniumylidene]-1,4-dihydropyridin-1-ylsulfonyl)azanide(1037211-09-8)
• EPA Substance Registry System: N-benzyloxycarbonyl-N'-(4-[dimethylazaniumylidene]-1,4-dihydropyridin-1-ylsulfonyl)azanide(1037211-09-8)

Safety Data

• Hazardous Substances Data: 1037211-09-8(Hazardous Substances Data)

Upstream product

• 1122-58-3 dmap 
• 1189-71-5 isocyanate de chlorosulfonyle 
• 100-51-6 benzyl alcohol 

Downstream Products

• 1356915-66-6 benzyl N-(pent-4-en-1-yl)sulfamoylcarbamate 
• 1648743-84-3 benzyl (N-(2,2-dimethylpent-4-en-1-yl)sulfamoyl)carbamate 
• 1548337-63-8 C₁₈H₂₂N₄O₆S 
• 1548337-71-8 C₂₉H₃₃F₂N₅O₇S 
• 1094677-96-9 6-N-t-butoxycarbonyl-2',3'-O-isopropylidene-5'-N-(N-[benzyloxycarbonyl]sulfamoyl)aminodeoxyadenosine 
• 1037211-15-6 C₄₄H₅₉N₃O₇S 
• 958264-18-1 C₁₆H₂₄N₂O₄S 
• 958264-17-0 C₁₈H₂₆N₂O₄S 
• 958264-19-2 benzyl N-(4-methyl-2,2-diphenylpent-4-en-1-yl)sulfamoylcarbamate 
• 958264-13-6 benzyl N-(2,2-diphenylpent-4-en-1-yl)sulfamoylcarbamate 
• 958264-16-9 benzyl N-(2,2-dimethylpent-4-en-1-yl)sulfamoylcarbamate 
• 958264-22-7 C₂₄H₃₀N₂O₄S 
• 958264-21-6 benzyl N-(2,2,4-triphenylpent-4-en-1-yl)sulfamoylcarbamate 

Relevant articles and documents

Mechanism-based inhibitors of MenE, an acyl-CoA synthetase involved in bacterial menaquinone biosynthesis

Menaquinone (vitamin K2) is an essential component of the electron transfer chain in many pathogens, including Mycobacterium tuberculosis and Staphylococcus aureus, and menaquinone biosynthesis is a potential target for antibiotic drug discovery. We report herein a series of mechanism-based inhibitors of MenE, an acyl-CoA synthetase that catalyzes adenylation and thioesterification of o-succinylbenzoic acid (OSB) during menaquinone biosynthesis. The most potent compound inhibits MenE with an IC50 value of 5.7 μM.

Structural Basis of Metallo-β-lactamase Inhibition by N-Sulfamoylpyrrole-2-carboxylates

Metallo-β-lactamases (MBLs) can efficiently catalyze the hydrolysis of all classes of β-lactam antibiotics except monobactams. While serine-β-lactamase (SBL) inhibitors (e.g., clavulanic acid, avibactam) are established for clinical use, no such MBL inhibitors are available. We report on the synthesis and mechanism of inhibition of N-sulfamoylpyrrole-2-carboxylates (NSPCs) which are potent inhibitors of clinically relevant B1 subclass MBLs, including NDM-1. Crystallography reveals that the N-sulfamoyl NH2 group displaces the dizinc bridging hydroxide/water of the B1 MBLs. Comparison of crystal structures of an NSPC and taniborbactam (VRNX-5133), presently in Phase III clinical trials, shows similar binding modes for the NSPC and the cyclic boronate ring systems. The presence of an NSPC restores meropenem efficacy in clinically derived E. coli and K. pneumoniae blaNDM-1. The results support the potential of NSPCs and related compounds as efficient MBL inhibitors, though further optimization is required for their clinical development.

ANTIBACTERIAL COMPOUNDS

This invention relates to compounds of formula (I) and methods of treatment using the compounds. The compounds of the invention can be used in combination with antibacterial agents to treat bacterial infections.More specifically, the compounds of formula (I) can be used in combination with a class of antibacterial agents known as carbapenems. The novel compounds of the present invention are enzyme inhibitors and more particularly are metallo-β-lactamase inhibitors.

TREATING DIABETES WITH DIPEPTIDYL PEPTIDASE-IV INHIBITORS

The present invention is directed to novel substituted dihydropyrrolopyrazoles of structural Formula I which are inhibitors of the dipeptidyl peptidase-N enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase IV enzyme is involved.

CYCLOPAMINE ANALOGS

The invention provides novel derivatives of cyclopamine having the following formula.